Article
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells
16 Oct 2014
Abstract excerpt
Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family members might offer an improved therapeutic approach. We show here that a novel seleno-α-keto acid triggers global histone acetylation in human colon cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
